SCHEMBL835689

SCHEMBL835689

Cc1ccc(NC(=S)Nc2ccc(Sc3cc(=O)n(C)c4ccc(C)cc34)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.41
TP53 P04637 1/20 0.41
PRNP P04156 1/20 0.41
MAPT P10636 4/20 0.40
ALDH1A1 P00352 3/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 2/20 0.40
GLA P06280 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
HPGD P15428 2/20 0.40
PKM P14618 1/20 0.40
JAK2 O60674 1/20 0.40
MARK4 Q96L34 1/20 0.39
THRB P10828 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL836066 0.87 RXFP1 (0.48) RXFP1TP53PRNPMAPTALDH1A1
SCHEMBL14302622 0.84 LMNA (0.41) RXFP1TP53PRNPMAPTALDH1A1
SCHEMBL836059 0.79 RHEB (0.50) RXFP1TP53PRNPMAPTALDH1A1
SCHEMBL835284 0.79 RXFP1 (0.43) RXFP1TP53PRNPMAPTALDH1A1
SCHEMBL829660 0.79 MEN1 (0.43) RXFP1TP53PRNPMAPTALDH1A1
SCHEMBL14302623 0.79 LMNA (0.43) RXFP1TP53PRNPMAPTALDH1A1
SCHEMBL835287 0.79 RXFP1 (0.43) RXFP1TP53PRNPMAPTALDH1A1
SCHEMBL835001 0.77 RXFP1 (0.44) RXFP1TP53PRNPMAPTALDH1A1
SCHEMBL14300144 0.76 RXFP1 (0.58) RXFP1TP53PRNPMAPTALDH1A1
SCHEMBL835232 0.75 KDM4E (0.44) RXFP1PRNPMAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds GTF3C4, HNF4A, TENT4A RXFP1 4782/4885TP53 335/4885PRNP 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.